|
|
|
|
|
|||||||
|
Session 28
Oral Abstract Session
Pharmacology of Antiretroviral Chemotherapeutic Agents: Pharmacokinetics and Therapeutic Drug Monitoring Wednesday, 11:15 am - 12:30 pm 6E |
| Moderator | David Burger, Univ.
Med. Ctr., Nijmegen, The Netherlands | ||
| 11:15 126. | Pharmacokinetics of Once-Daily vs Twice-Daily Kaletra (Lopinavir/Ritonavir) in HIV+ Subjects R. Bertz*, C. Foit, X. Ye, L. Manning, B. Bernstein, C. Renz, A. Hsu, M. King, G. R. Granneman, and E. Sun Abbott Labs., Abbott Park, IL
| ||
| 11:30 127. | Reduced Accumulation of Ritonavir and Saquinavir in PBMCs in Vivo is Associated with Increased P-gp and MRP1 Expression in HIV-Infected Individuals E. Meaden*1, P. Hoggard1, P. Newton2, J. F. Tjia1, D. Aldam2, D. Cornforth2, J. Lloyd1, A. Smith2, I. Williams2, N. Beeching3, E. Stockwell4, E. Wilkins4, P. Carey5, D. Back1, and S. Khoo1 1Univ. of Liverpool; 2Mortimer Market Centre, London; 3Univ. Hosp. Aintree, Liverpool; 4North Manchester Gen. Hosp; and 5Royal Liverpool Univ. Hosp., UK
| ||
| 11:45 128. | The Normalized Inhibitory Quotient (NIQ) of Lopinavir Is Predictive of Viral Load Response over 48 Weeks in a Cohort of Highly Experienced HIV-1-Infected Individuals A. Castagna*1, A. Danise1, H. Hasson1, E. Boeri1, A. Lazzarin1, M. Peeters2, S. Piscitelli2, and R. Hoetelmans2 1Hosp. San Raffaele, Milan, Italy and 2Tibotec-Virco, Rockville, MD, and Mechelen, Belgium
| ||
| 12:00 129. | The Inhibitory Quotient (IQ) for Saquinavir (SQV) Predicts Virologic Response to Salvage Therapy C. V. Fletcher*1, H. Cheng2, S. A. Fiscus3, R. Swanstrom3, N. S. Hellmann4, R. Haubrich5, D. Katzenstein6, and R. Gulick7 for the ACTG 359 Team 1Univ. of Minnesota, Minneapolis; 2Harvard Sch. of Publ. Hlth., Boston, MA; 3Univ. of North Carolina, Chapel Hill; 4ViroLogic Inc., South San Francisco, CA; 5Univ. of California, San Diego; 6Stanford Univ. Med. Ctr., Palo Alto, CA; and 7Weill Med. Coll. of Cornell Univ., New York, NY
| ||
| 12:15 130. | The Use of Virtual Inhibitory Quotient (VIQ) in Antiretroviral (ART)-Experienced Patients Taking Amprenavir/Lopinavir Combinations E. Phillips*1, A. Tseng 2, S. Walker 1, M. Loutfy2, S. Walmsley 2, S. Tailor1, and P. R. Harrigan3 1Sunnybrook & Women's Coll. Hlth. Sci. Ctr.; 2Univ. Hlth. Network, Toronto, ON; and 3British Columbia Ctr. for Excellence in HIV/AIDS, Vancouver, Canada
|
